ProTrials Named One of the Fastest-Growing Companies and a Top Women-Owned Business
Mountain View, CA
ProTrials Research Inc., announced that it has earned a spot for the third consecutive year on Inc. Magazine’s Inc. 5000, an exclusive list of the fastest growing private companies in the U.S., and the Silicon Valley/San Jose Business Journal’s top women-owned businesses, a list of the largest public and private Silicon Valley women-owned businesses. The contract research organization (CRO) achieved these rankings based on revenue figures.
Inc. 5000 companies are chosen based on company’s year over year revenue growth for the past three years. To be considered, companies must be U.S.-based and privately held, for profit and independent – not subsidiaries or divisions of other companies. The 5000 companies that made the list reported aggregate revenue of $214 billion and median three-year growth of 126 percent.
The Silicon Valley/San Jose Business Journal list of the top 25 women-owned businesses ranks area public and private women-owned companies according to revenue.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
